acradvancesanifrolumabaprilbelimumabbeyondcellchallengescongresscontroversiesdailydaydiscussingefficacyemergingerythematosuseularfebruaryguidelineshighlightsinsightsjanuaryjulyjunelnmarchmaymonthlynephritisnkoutcomespreviewpublicationsreviewrisingrituximabsafetysletelitacicepttherapiestherapytreatmenttreatments